Biotech News

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance

Si-Bone (SIBN)Si-BoneEarnings

Delivered ~20% U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $55.7 million, representing growth of 14.5% U.S. revenue of $52.8 million, representing growth of 13.9% Gross margin of

Related news

Si-Bone

Spinopelvic Procedural Solutions SI-BONE is a global medical-device company developing procedural solutions for patients with compromised bone, with a particular focus on the sacropelvic and spinopelvic anatomy. iFuse Technology Platform Its portfolio is built around the iFuse family of implants and instruments. Products include...

Recent company news

Stock data

Close
23.75 USD
Market cap
621.33M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States